(Q35503645)

8 August 2017

title

Management of high-risk localized prostate cancer (English)

1 reference

8 August 2017

1 reference

Ariel E Marciscano

1

1 reference

8 August 2017

Matthew E Hardee

series ordinal

2

1 reference

8 August 2017

Nicholas Sanfilippo

series ordinal

3

1 reference

8 August 2017

publication date

1 November 2011

1 reference

8 August 2017

1 reference

8 August 2017

volume

2012

1 reference

8 August 2017

page(s)

641689

1 reference

Creative Commons Attribution 3.0 Unported

8 August 2017

copyright license

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Hormone therapy in the management of prostate cancer: evidence-based approaches

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Abiraterone and increased survival in metastatic prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

27 July 2018

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Early clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Treatment strategies for high-risk locally advanced prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Treatment of locally advanced prostate cancer: is chemotherapy the next step?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Controversies in the management of advanced prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Concurrent paclitaxel and radiation therapy for breast cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Long-term Survival Among Men With Conservatively Treated Localized Prostate Cancer

27 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for hi

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

An enhanced prognostic system for clinically localized carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Duration of androgen suppression in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Cell cycle G2/M arrest and activation of cyclin-dependent kinases associated with low-dose paclitaxel-induced sub-G1 apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Combination of taxanes with radiation: preclinical studies

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3206331

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

26 September 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F641689

Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer

21 January 2018

1 reference

12 December 2020

Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy

1 reference

12 December 2020

1 reference

12 December 2020

Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

1 reference

12 December 2020

Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer

1 reference

12 December 2020

Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer

1 reference

12 December 2020

Docetaxel enhances tumor radioresponse in vivo

1 reference

12 December 2020

Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients

1 reference

12 December 2020

A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy

1 reference

12 December 2020

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

12 December 2020

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate Cancer

1 reference

12 December 2020

Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation

1 reference

12 December 2020

VMAT vs. 7-field-IMRT: assessing the dosimetric parameters of prostate cancer treatment with a 292-patient sample

1 reference

12 December 2020

A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988–2006

1 reference

12 December 2020

Assessing the role of volumetric modulated arc therapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer

1 reference

12 December 2020

Does helical tomotherapy improve dose conformity and normal tissue sparing compared to conventional IMRT? A dosimetric comparison in high risk prostate cancer

1 reference

12 December 2020

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

12 December 2020

Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables

1 reference

12 December 2020

Radiation Therapy Oncology Group 0521: A Phase III Randomized Trial of Androgen Suppression and Radiation Therapy Versus Androgen Suppression and Radiation Therapy Followed by Docetaxel/Prednisone for Localized, High-Risk Prostate Cancer

1 reference

12 December 2020

Disease progression following radical prostatectomy in men with Gleason score 7 tumor

1 reference

12 December 2020

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

12 December 2020

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

1 reference

12 December 2020

Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system

1 reference

12 December 2020

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

12 December 2020

A challenge to contemporary management of prostate cancer

1 reference

12 December 2020

Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy

1 reference

12 December 2020

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

12 December 2020

Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells

1 reference

12 December 2020

Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease

1 reference

12 December 2020

Identifiers

DOI

10.1155/2012/641689

1 reference

8 August 2017

1 reference

8 August 2017

1 reference